Publications by authors named "Odile Beyne-Rauzy"

Claim this Profile
L
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with mutant MDS/AML.
David A Sallman, Rami S Komrokji, Amy E Dezern, Marie Sebert, Guillermo Garcia-Manero, Odile Beyne-Rauzy

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Odile Beyne-Rauzy

Leukemia· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
Vincent Jachiet, Laure Ricard, Pierre Hirsch, Florent Malard, Laurent Pascal, Odile Beyne-Rauzy

Clin Exp Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting patients' oncological treatment through remote participation of general practitioners in multi-disciplinary consultation meetings: A feasibility study.
Vladimir Druel, Laetitia Gimenez, Paul Tachousin, Nathalie Boussier, Eric Bauvin, Odile Beyne-Rauzy

Eur J Gen Pract· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Arsene Mekinian, Lin Pierre Zhao, Sylvie Chevret, Kristell Desseaux, Laurent Pascal

Leukemia· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Lionel Adès, Nicolas Duployez, Agnes Guerci-Bresler, Kamel Laribi, Pierre Peterlin, Odile Beyne-Rauzy

Br J Haematol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
Marie Péan de Ponfilly-Sotier, Vincent Jachiet, Ygal Benhamou, Constance Lahuna, Benoit De Renzis, Odile Beyne-Rauzy

Clin Exp Rheumatol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMEN-France Registry.
Aurélien Sokal, Thomas de Nadaï, Julien Maquet, Thibault Comont, Nicolas Limal, Odile Beyne-Rauzy

Br J Haematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study.
Guillaume Moulis, Johanne Germain, Manuela Rueter, Margaux Lafaurie, Myriam Aroichane, Odile Beyne-Rauzy

Am J Hematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory myopathies associated with myelodysplastic syndromes: A French multicenter case control study and literature review.
Antoine Briantais, Julie Séguier, Benjamin De Sainte Marie, Arsène Mekinian, Cristina Belizna, Odile Beyne-Rauzy

Semin Arthritis Rheum· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
Thibault Comont, Mathieu Meunier, Amina Cherait, Clemence Santana, Thomas Cluzeau, Odile Beyne-Rauzy

Br J Haematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a comprehensive geriatric assessment on decision-making in older patients with hematological malignancies.
Marie Garric, Sandrine Sourdet, Bastien Cabarrou, Zara Steinmeyer, Martin Gauthier, Odile Beyne-Rauzy

Eur J Haematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eprenetapopt Plus Azacitidine in -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).
Thomas Cluzeau, Marie Sebert, Ramy Rahmé, Stefania Cuzzubbo, Jacqueline Lehmann-Che

J Clin Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Vincent Jachiet, Guillaume Moulis, Jérome Hadjadj, Julie Seguier, Kamel Laribi, Odile Beyne-Rauzy

Haematologica· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL-Negative Myeloproliferative Neoplasms.
Julie Belliere, Magali Colombat, Clément Kounde, Christian Recher, David Ribes, Odile Beyne-Rauzy

Kidney Int Rep· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small Private Online Course in Teaching Oncology-Feedback After 1 Year: What Lessons?
Charlotte Vaysse, Anne-Laure Fize, Fabien Despas, Elodie Chantalat, Elie Serrano, Odile Beyne-Rauzy

J Cancer Educ· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry.
Guillaume Moulis, Thibault Comont, Johanne Germain, Agnès Sommet, Maryse Lapeyre-Mestre, Odile Beyne-Rauzy

Blood Adv· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positivity rate of systematic bone marrow smear in patients over 60 years old with newly diagnosed immune thrombocytopenia.
Thibault Comont, Johanne Germain, Odile Beyne-Rauzy, Daniel Adoue, Guillaume Moulis

Blood Adv· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.
Louise de Swart, Simon Crouch, Marlijn Hoeks, Alex Smith, Saskia Langemeijer, Odile Beyne-Rauzy

Haematologica· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Pierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, Guillermo Garcia-Manero, Rena Buckstein, Odile Beyne-Rauzy

N Engl J Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab-induced eosinophilic fasciitis: a case report.
Natasha Ollier, Emilie Tournier, Nicolas Meyer, Vincent Sibaud, Cécile Pages-Laurent, Odile Beyne-Rauzy

Rheumatol Adv Pract· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Marie Sébert, Aline Renneville, Cécile Bally, Pierre Peterlin, Odile Beyne-Rauzy

Haematologica· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitor-related acral vasculitis.
Thibault Comont, Vincent Sibaud, Loïc Mourey, Pierre Cougoul, Odile Beyne-Rauzy

J Immunother Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
María Díez-Campelo, Jose I Lorenzo, Raphael Itzykson, Silvia M Rojas, Céline Berthon, Odile Beyne-Rauzy

Br J Haematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload.
Christian Rose, Caroline Lenoir, Emmanuel Gyan, Maya Hacini, Shanti Amé, Odile Beyne-Rauzy

Eur J Haematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis